Found 7 matching trials
A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma
PHASE2Currently, there is no widely used adjuvant treatment available to improve ...
Location
VU Medical Centere
A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma
PHASE2The goal of the Phase 1 study was to find the recommended Phase 2 dose of t...
Location
The University of Arizona Cancer Center
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
PHASE1This is a Phase 1b study that incorporates dose expansion cohorts to furthe...
Location
Scottsdale Healthcare Hospitals DBA Honor Health
Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients
PHASE1Phase 1, randomized, double-blind, placebo-controlled, dose-escalation stud...
Location
Multiple Locations
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
PHASE2A Phase 2 study intended to see efficacy of tilsotolimod in combination wit...
Status
Active Not Recruiting
Location
Banner University Medical Center Tucson Campus
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
PHASE3A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced me...
Location
University of Alabama at Birmingham (UAB)
Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients
PHASE1First-in-humans, phase 1, dose-escalation study with 4 dose levels of singl...
Location
University of Colorado Hospital